French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced ...

Provention Bio's anti-CD3 monoclonal antibody teplizumab – partnered with Sanofi – became the first immunotherapy to launch for type 1 diabetes after it was approved by the FDA as Tzield last ...

and €10 million in Lyon Gerland to produce Tzield (teplizumab), a biologic for type 1 diabetes that Sanofi acquired last year from Provention Bio in a $2.9 billion deal. “With these ...

The booth of France's largest healthcare company, Sanofi, showcases the innovative treatment Tzield, the world's first and only disease modifying therapy to delay the onset of type 1 diabetes and ...